March's top stories: Perrigo's $2.85bn sale, Cancer Research UK's Precision Panc project

Perrigo completed the sale of Tysabri drug royalty to RPI for $2.85bn, London's Institute of Cancer Research (ICR) revealed new secrets about the genetic causes of cancer, and Eli Lilly acquired CoLucid Pharmaceuticals for $960m. Pharmaceutical-techn …
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news